Secondary hyperaldosteronism historical perspective

	Secondary hyperaldosteronism Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Secondary Hyperaldosteronism from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
CT scan Findings
MRI Findings
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Case Studies
Case #1
Secondary hyperaldosteronism historical perspective On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Secondary hyperaldosteronism historical perspective All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Secondary hyperaldosteronism historical perspective
CDC on Secondary hyperaldosteronism historical perspective
Secondary hyperaldosteronism historical perspective in the news
Blogs on Secondary hyperaldosteronism historical perspective
Directions to Hospitals Treating Conn syndrome
Risk calculators and risk factors for Secondary hyperaldosteronism historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Mehrian Jafarizade, M.D [2]

Overview

From 1960s to early 1970s, its techniques of diagnosis and treatment were greatly improved by the availability of spironolactone, realization of the renin-angiotensin-aldosterone system, and progress in laboratory tests and adrenal venous sampling.
On October 19, 1964, Jerome W. Conn, Edwin L. Cohen and David R. Rovner differentiated between primary and secondary aldosteronism in hypertensive disease.^[1]
In 1970s, there was an extensive application of modern imaging modalities, such as CT scanning, adrenal venous sampling and steroid analysis.^[2]

↑ Conn JW, Cohen EL, Rovner DR (1985). "Landmark article Oct 19, 1964: Suppression of plasma renin activity in primary aldosteronism. Distinguishing primary from secondary aldosteronism in hypertensive disease. By Jerome W. Conn, Edwin L. Cohen and David R. Rovner". JAMA. 253 (4): 558–66. PMID 3881606.
↑ Lingam RK, Sohaib SA, Vlahos I, Rockall AG, Isidori AM, Monson JP, Grossman A, Reznek RH (2003). "CT of primary hyperaldosteronism (Conn's syndrome): the value of measuring the adrenal gland". AJR Am J Roentgenol. 181 (3): 843–9. doi:10.2214/ajr.181.3.1810843. PMID 12933492.